Home » Topics » BioWorld

BioWorld
RSS

S.R. ONE EXERCISES RIBI WARRANTS

Oct. 25, 1991

$1.27M GRANT FOR TAXOL STUDY

Oct. 25, 1991

GM-CSF HELPS IMMUNEX TO PROFITABLE QUARTER

Oct. 25, 1991

IMCLONE FILES FOR 2 MILLION-SHARE IPO

Oct. 25, 1991

BCG SHOWS PROMISE AGAINST BLADDER CANCER

Oct. 25, 1991

OXFORD, FAIRFIELD PLAN BIOSCIENCE FUND

Oct. 25, 1991

FDA APPROVES GROWTH DRUG

Oct. 24, 1991

REPLIGEN STAGGERS AFTER SPLIT WITH MERCK

Oct. 24, 1991

INTERFERON SCIENCES RAISES $8.5 MILLION

Oct. 24, 1991

AGOURON COMPLETES 2 MILLION-SHARE OFFERING

Oct. 24, 1991

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...